POSTER: CLL-563 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings From an Ongoing Phase 1a Study
Zulfa Omer(University of Cincinnati), Talha Munir(Leeds Teaching Hospitals NHS Trust), Prioty Islam(Kettering University), Michał Kwiatek(Institute of Plant Genetics, Polish Academy of Sciences), Danielle M. Brander(Duke University), Sarah G. Injac(Baylor College of Medicine), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), John C. Byrd(University of Cincinnati), Francesco Forconi(University of Leeds), Shuo Ma(Nantong University), Dima El‐Sharkawi(Royal Marsden Hospital), Alvaro J. Alencar(University of Miami), Nirav N. Shah(Medical College of Wisconsin), Jeffery Smith(Clatterbridge Cancer Centre NHS Foundation Trust), Graham P. Collins(Churchill Hospital), Jonathon B. Cohen(Emory University), Jane Robertson(AstraZeneca (United Kingdom)), Allison Winter(Cleveland Clinic)
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454